{"id":48943,"date":"2025-11-25T16:36:28","date_gmt":"2025-11-25T08:36:28","guid":{"rendered":"https:\/\/flcube.com\/?p=48943"},"modified":"2025-11-25T16:36:29","modified_gmt":"2025-11-25T08:36:29","slug":"biogen-dayra-partnership-targets-immunology-with-macrocyclic-peptides","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48943","title":{"rendered":"Biogen Dayra Partnership Targets Immunology with Macrocyclic Peptides"},"content":{"rendered":"\n<p><strong>Biogen Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/BIIB:NASDAQ\">NASDAQ: BIIB<\/a>) and <strong>Dayra Therapeutics<\/strong> announced a research collaboration to discover and develop <strong>oral macrocyclic peptides<\/strong> for priority immunology targets, with Biogen paying <strong>$50\u202fmillion upfront<\/strong> and gaining options to acquire development candidates plus milestones.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure\">Deal Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Partner<\/strong><\/td><td>Dayra Therapeutics<\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td>USD\u202f50\u202fmillion<\/td><\/tr><tr><td><strong>Option Terms<\/strong><\/td><td>Biogen may acquire development candidates for additional payment per program<\/td><\/tr><tr><td><strong>Milestones<\/strong><\/td><td>Preclinical and clinical development milestone payments per program<\/td><\/tr><tr><td><strong>Biogen\u2019s Role<\/strong><\/td><td>Advance molecules through development and commercialization, including manufacturing<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>Oral macrocyclic peptides for high\u2011priority immunological targets<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-profile\">Technology Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Class:<\/strong> Oral macrocyclic peptides<\/li>\n\n\n\n<li><strong>Advantages:<\/strong> Oral administration, higher specificity, ability to target protein binding sites inaccessible to traditional small molecules<\/li>\n\n\n\n<li><strong>Application:<\/strong> Immunological conditions with challenging targets<\/li>\n\n\n\n<li><strong>Development Stage:<\/strong> Early\u2011stage discovery and optimization<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Expansion:<\/strong> Enhances Biogen\u2019s strategy to build a <strong>differentiated immunology pipeline<\/strong> beyond its neurology core<\/li>\n\n\n\n<li><strong>Platform Value:<\/strong> Macrocyclic peptides offer novel mechanism of action in crowded immunology space<\/li>\n\n\n\n<li><strong>Risk Mitigation:<\/strong> Collaboration structure allows Biogen to validate technology before full acquisition<\/li>\n\n\n\n<li><strong>Speed:<\/strong> Dayra\u2019s platform accelerates candidate identification and optimization<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><\/tr><\/thead><tbody><tr><td><strong>Global Immunology Market<\/strong><\/td><td>$95\u202fbillion (2024)<\/td><\/tr><tr><td><strong>Growth CAGR<\/strong><\/td><td>7\u20119%<\/td><\/tr><tr><td><strong>Addressable Population<\/strong><\/td><td>Millions across rheumatology, dermatology, gastroenterology<\/td><\/tr><tr><td><strong>Peak Sales Potential<\/strong><\/td><td><strong>$500\u2011800\u202fmillion<\/strong> per successful program if approved<\/td><\/tr><tr><td><strong>Competitive Edge:<\/strong> First\u2011mover advantage in oral macrocyclic peptides for immunology vs. injectable biologics<\/td><td><\/td><\/tr><tr><td><strong>Next Catalyst:<\/strong> Lead candidate nomination expected <strong>H2\u202f2026<\/strong><\/td><td><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the Biogen\u2011Dayra collaboration, development timelines, and market potential. Actual results may differ materially due to risks including preclinical\u2011to\u2011clinical translation, competitive dynamics, and regulatory challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biogen Inc. (NASDAQ: BIIB) and Dayra Therapeutics announced a research collaboration to discover and develop&#8230;<\/p>\n","protected":false},"author":1,"featured_media":48958,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[351,4473,993],"class_list":["post-48943","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-biogen","tag-dayra-therapeutics","tag-nasdaq-biib"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Biogen Dayra Partnership Targets Immunology with Macrocyclic Peptides - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Biogen Inc. (NASDAQ: BIIB) and Dayra Therapeutics announced a research collaboration to discover and develop oral macrocyclic peptides for priority immunology targets, with Biogen paying $50\u202fmillion upfront and gaining options to acquire development candidates plus milestones.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=48943\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biogen Dayra Partnership Targets Immunology with Macrocyclic Peptides\" \/>\n<meta property=\"og:description\" content=\"Biogen Inc. (NASDAQ: BIIB) and Dayra Therapeutics announced a research collaboration to discover and develop oral macrocyclic peptides for priority immunology targets, with Biogen paying $50\u202fmillion upfront and gaining options to acquire development candidates plus milestones.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=48943\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-25T08:36:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-25T08:36:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2502.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48943#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48943\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Biogen Dayra Partnership Targets Immunology with Macrocyclic Peptides\",\"datePublished\":\"2025-11-25T08:36:28+00:00\",\"dateModified\":\"2025-11-25T08:36:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48943\"},\"wordCount\":273,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48943#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2502.webp\",\"keywords\":[\"Biogen\",\"Dayra Therapeutics\",\"NASDAQ: BIIB\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48943#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48943\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=48943\",\"name\":\"Biogen Dayra Partnership Targets Immunology with Macrocyclic Peptides - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48943#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48943#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2502.webp\",\"datePublished\":\"2025-11-25T08:36:28+00:00\",\"dateModified\":\"2025-11-25T08:36:29+00:00\",\"description\":\"Biogen Inc. (NASDAQ: BIIB) and Dayra Therapeutics announced a research collaboration to discover and develop oral macrocyclic peptides for priority immunology targets, with Biogen paying $50\u202fmillion upfront and gaining options to acquire development candidates plus milestones.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48943#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48943\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48943#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2502.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2502.webp\",\"width\":1080,\"height\":608,\"caption\":\"Biogen Dayra Partnership Targets Immunology with Macrocyclic Peptides\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48943#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biogen Dayra Partnership Targets Immunology with Macrocyclic Peptides\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biogen Dayra Partnership Targets Immunology with Macrocyclic Peptides - Insight, China&#039;s Pharmaceutical Industry","description":"Biogen Inc. (NASDAQ: BIIB) and Dayra Therapeutics announced a research collaboration to discover and develop oral macrocyclic peptides for priority immunology targets, with Biogen paying $50\u202fmillion upfront and gaining options to acquire development candidates plus milestones.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=48943","og_locale":"en_US","og_type":"article","og_title":"Biogen Dayra Partnership Targets Immunology with Macrocyclic Peptides","og_description":"Biogen Inc. (NASDAQ: BIIB) and Dayra Therapeutics announced a research collaboration to discover and develop oral macrocyclic peptides for priority immunology targets, with Biogen paying $50\u202fmillion upfront and gaining options to acquire development candidates plus milestones.","og_url":"https:\/\/flcube.com\/?p=48943","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-25T08:36:28+00:00","article_modified_time":"2025-11-25T08:36:29+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2502.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=48943#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=48943"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Biogen Dayra Partnership Targets Immunology with Macrocyclic Peptides","datePublished":"2025-11-25T08:36:28+00:00","dateModified":"2025-11-25T08:36:29+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=48943"},"wordCount":273,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=48943#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2502.webp","keywords":["Biogen","Dayra Therapeutics","NASDAQ: BIIB"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=48943#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=48943","url":"https:\/\/flcube.com\/?p=48943","name":"Biogen Dayra Partnership Targets Immunology with Macrocyclic Peptides - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=48943#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=48943#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2502.webp","datePublished":"2025-11-25T08:36:28+00:00","dateModified":"2025-11-25T08:36:29+00:00","description":"Biogen Inc. (NASDAQ: BIIB) and Dayra Therapeutics announced a research collaboration to discover and develop oral macrocyclic peptides for priority immunology targets, with Biogen paying $50\u202fmillion upfront and gaining options to acquire development candidates plus milestones.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=48943#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=48943"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=48943#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2502.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2502.webp","width":1080,"height":608,"caption":"Biogen Dayra Partnership Targets Immunology with Macrocyclic Peptides"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=48943#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Biogen Dayra Partnership Targets Immunology with Macrocyclic Peptides"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2502.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48943","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48943"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48943\/revisions"}],"predecessor-version":[{"id":48961,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48943\/revisions\/48961"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/48958"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48943"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48943"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48943"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}